Allumin8 CEO Alyssa Huffman discusses the company's novel therapeutic hardware during an interview with SmartTRAK at the 2025 NASS Biologic Interventions.
Alyssa Huffman, CEO of Allumin8, discussed the company and its efforts to create a new product category of therapeutic hardware in an interview with SmartTRAK on May 9, 2025, at the 2025 North American Spine Society (NASS) Biologics Interventions meeting in Chicago, Illinois. The company is focused on treating over 200 unique bone disorders and diseases, and its first product is focused on the Spinal Hardware Market.
Click on the following video (8:49 min) to learn more. A link to download a complete transcript of the interview is also provided below.
SmartTRAK: Hi, this is Erin Dorgan, senior analyst here at SmartTRAK. I'm here today with Alyssa Huffman, CEO of ALLUMIN8. Alyssa, thank you for joining me today. Can you share a little bit more about your background and your role at ALLUMIN8?
Alyssa Huffman: Absolutely, Erin. Thanks for being here. I started in the clinic, then worked in the OR, went into sales, distribution. I worked my way into an executive function and then decided I was going to bet on myself. I have 30 years of experience throughout orthopedic spine biologics regenerative therapies.
That's awesome.
AH: And computer navigation.
Well, that's quite extensive. So we're here today at the NASS Biologic Interventions for Spinal Pathologies meeting. Why are you here with ALLUMIN8? What's the purpose for ALLUMIN8 presenting?
AH: Dr. Zorica Buser, she asked me to come and talk to the researchers and physicians about how to design a product that will actually commercialize and can get funded. There's a very different issue that's going on right now where products that only are a little bit, 1% to 3%, better than what's currently available on the market. There's a plethora of those, and so we have ...
